MP0712 Advances to Higher Dose; H1 2026 Cash Runway Extends into Late 2027
MOLN sits 29% above its 52-week low of $3.41 on light trading volume (0.3× avg).
Summary
Molecular Partners reported H1 2026 results and announced MP0712 advanced to dose level 2 in its Phase 1/2a trial, with CD70 selected as the next RDT target. Cash of CHF 67.9M funds operations into late 2027.
Key Events · Product Development and Regulatory · MOLN
-
MP0712 Advances to Dose Level 2
Cohort 1 (75 MBq per dose) fully recruited with no dose-limiting events; all adverse events were grade 1-2 and transient. Dose Escalation Review Committee cleared progression to cohort 2 (105 MBq per dose), now open and recruiting.
-
CD70 Selected as Third RDT Target
CD70, overexpressed in clear cell renal cell carcinoma, chosen for the radiopharmaceutical pipeline. IND-enabling work begins H2 2026 with clinical entry slated for 2027.
-
H1 2026 Financials and Runway
Net loss of CHF 26.7M (vs CHF 37.2M in H1 2025) on zero revenue. Cash and equivalents of CHF 67.9M (~USD 84M) expected to fund operations into late 2027.
-
FY2026 Expense Guidance Maintained
Total operating expenses of CHF 45-55M reaffirmed at constant exchange rates, including ~CHF 6M of non-cash share-based payment, pension, and depreciation costs.
Analysis · MOLN · Life Sciences
The lead Radio-DARPin MP0712 cleared its first safety hurdle and moved to a higher therapeutic dose in the Phase 1/2a SCLC trial, with no dose-limiting events in cohort 1. The company also named CD70 as its third radiopharmaceutical target and confirmed CHF 67.9 million in cash funds operations into late 2027. For a clinical-stage biotech with a $178M market cap, the dose escalation de-risks the lead program while the runway removes near-term financing overhang.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MOLN was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.6M. The 52-week trading range was $3.41 to $5.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.